200 related articles for article (PubMed ID: 37899424)
1. Loss of CDH16 expression is a strong independent predictor for lymph node metastasis in Middle Eastern papillary thyroid cancer.
Siraj AK; Parvathareddy SK; Al-Rasheed M; Annaiyappanaidu P; Siraj N; Lennartz M; Al-Sobhi SS; Al-Dayel F; Sauter G; Al-Kuraya KS
Sci Rep; 2023 Oct; 13(1):18559. PubMed ID: 37899424
[TBL] [Abstract][Full Text] [Related]
2. Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China.
Huang M; Yan C; Xiao J; Wang T; Ling R
Diagn Pathol; 2019 Jul; 14(1):74. PubMed ID: 31300059
[TBL] [Abstract][Full Text] [Related]
3. Association between diffuse lymphocytic infiltration and papillary thyroid cancer aggressiveness according to the presence of thyroid peroxidase antibody and BRAF
Lee YK; Park KH; Park SH; Kim KJ; Shin DY; Nam KH; Chung WY; Lee EJ
Head Neck; 2018 Oct; 40(10):2271-2279. PubMed ID: 29935011
[TBL] [Abstract][Full Text] [Related]
4. Risk and Prognostic Factors for BRAF
Wei X; Wang X; Xiong J; Li C; Liao Y; Zhu Y; Mao J
Biomed Res Int; 2022; 2022():9959649. PubMed ID: 35647194
[TBL] [Abstract][Full Text] [Related]
5. Associations of the BRAF V600E Mutation and PAQR3 Protein Expression with Papillary Thyroid Carcinoma Clinicopathological Features.
Gao J; Ma XP; Deng FS; Jiang L; Jia WD; Li M
Pathol Oncol Res; 2020 Jul; 26(3):1833-1841. PubMed ID: 31758408
[TBL] [Abstract][Full Text] [Related]
6. The role of molecular markers and tumor histological type in central lymph node metastasis of papillary thyroid carcinoma.
Paulson L; Shindo M; Schuff K; Corless C
Arch Otolaryngol Head Neck Surg; 2012 Jan; 138(1):44-9. PubMed ID: 22249628
[TBL] [Abstract][Full Text] [Related]
7. Predicting Factors for Bilaterality in Papillary Thyroid Carcinoma with Tumor Size <4 cm.
Kim SK; Park I; Woo JW; Lee JH; Choe JH; Kim JH; Kim JS
Thyroid; 2017 Feb; 27(2):207-214. PubMed ID: 27750022
[TBL] [Abstract][Full Text] [Related]
8. MUC1 expression in papillary thyroid carcinoma is associated with BRAF mutation and lymph node metastasis; the latter is the most important risk factor of relapse.
Renaud F; Gnemmi V; Devos P; Aubert S; Crépin M; Coppin L; Ramdane N; Bouchindhomme B; d'Herbomez M; Van Seuningen I; Do Cao C; Pattou F; Carnaille B; Pigny P; Wémeau JL; Leteurtre E
Thyroid; 2014 Sep; 24(9):1375-84. PubMed ID: 25012490
[TBL] [Abstract][Full Text] [Related]
9. X-linked inhibitor of apoptosis protein (XIAP) predicts disease-free survival in
Parvathareddy SK; Siraj AK; Bu R; Iqbal K; Al-Rasheed M; Al-Haqawi W; Annaiyappanaidu P; Siraj N; Ahmed SO; Al-Sobhi SS; Al-Dayel F; Al-Kuraya KS
Front Endocrinol (Lausanne); 2022; 13():1054882. PubMed ID: 36578953
[TBL] [Abstract][Full Text] [Related]
10. Correlation between genetic alterations and clinicopathological features of papillary thyroid carcinomas.
Shang S; Yang H; Chen M; Wu J; Shi X; Li X; Feng N; Zheng Z; Liu H; Zhang Y
J Int Med Res; 2024 Mar; 52(3):3000605241233166. PubMed ID: 38456650
[TBL] [Abstract][Full Text] [Related]
11. A meta-analysis evaluating the relationship between B-type Raf kinase mutation and cervical lymphatic metastasis in papillary thyroid cancer.
Ma H; Wang R; Fang J; Zhong Q; Chen X; Hou L; Feng L; Chen X; Huang Z; Zhao H
Medicine (Baltimore); 2020 Jan; 99(5):e18917. PubMed ID: 32000400
[TBL] [Abstract][Full Text] [Related]
12. BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis.
Li C; Lee KC; Schneider EB; Zeiger MA
J Clin Endocrinol Metab; 2012 Dec; 97(12):4559-70. PubMed ID: 23055546
[TBL] [Abstract][Full Text] [Related]
13. Risk Factors for Neck Nodal Metastasis in Papillary Thyroid Cancer With BRAF V600E Mutation.
Han Y; Hou L; Zhao B; Gao L; Li S
Front Endocrinol (Lausanne); 2022; 13():884428. PubMed ID: 35784548
[TBL] [Abstract][Full Text] [Related]
14. BRAF(V600E) mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness.
Kurtulmus N; Duren M; Ince U; Cengiz Yakicier M; Peker O; Aydın O; Altiok E; Giray S; Azizlerli H
Endocrine; 2012 Oct; 42(2):404-10. PubMed ID: 22426956
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of CDH16 in Papillary Thyroid Cancer and Its Potential Molecular Mechanism Analysed by qRT-PCR, TCGA and in silico Analysis.
Li P; Wu Q; Sun Y; Pan X; Han Y; Ye B; Zhang Y; Dong J; Zheng Z
Cancer Manag Res; 2019; 11():10719-10729. PubMed ID: 31920382
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Significance of COX-2 Overexpression in
Parvathareddy SK; Siraj AK; Annaiyappanaidu P; Al-Sobhi SS; Al-Dayel F; Al-Kuraya KS
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33327467
[TBL] [Abstract][Full Text] [Related]
17. TERT Promoter Mutations and Tumor Persistence/Recurrence in Papillary Thyroid Cancer.
Myung JK; Kwak BK; Lim JA; Lee MC; Kim MJ
Cancer Res Treat; 2016 Jul; 48(3):942-7. PubMed ID: 26727717
[TBL] [Abstract][Full Text] [Related]
18. Effects of Coexistent BRAF
Moon S; Song YS; Kim YA; Lim JA; Cho SW; Moon JH; Hahn S; Park DJ; Park YJ
Thyroid; 2017 May; 27(5):651-660. PubMed ID: 28181854
[TBL] [Abstract][Full Text] [Related]
19. Effect and Interactions of BRAF on Lymph Node Metastasis in Papillary Thyroid Carcinoma With Hashimoto Thyroiditis.
Li P; Liu Y; Wei T; Wang X; Zhu J; Yang R; Gong Y; Zhao W
J Clin Endocrinol Metab; 2024 Mar; 109(4):944-954. PubMed ID: 37967234
[TBL] [Abstract][Full Text] [Related]
20. BRAF V600E Status Sharply Differentiates Lymph Node Metastasis-associated Mortality Risk in Papillary Thyroid Cancer.
Tao Y; Wang F; Shen X; Zhu G; Liu R; Viola D; Elisei R; Puxeddu E; Fugazzola L; Colombo C; Jarzab B; Czarniecka A; Lam AK; Mian C; Vianello F; Yip L; Riesco-Eizaguirre G; Santisteban P; O'Neill CJ; Sywak MS; Clifton-Bligh R; Bendlova B; Sýkorová V; Zhao S; Wang Y; Xing M
J Clin Endocrinol Metab; 2021 Oct; 106(11):3228-3238. PubMed ID: 34273152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]